KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Halozyme Therapeutics (HALO) over the last 17 years, with Q3 2025 value amounting to $419.7 million.

  • Halozyme Therapeutics' Cash & Equivalents rose 17194.82% to $419.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $419.7 million, marking a year-over-year increase of 17194.82%. This contributed to the annual value of $115.8 million for FY2024, which is 212.89% down from last year.
  • Halozyme Therapeutics' Cash & Equivalents amounted to $419.7 million in Q3 2025, which was up 17194.82% from $61.9 million recorded in Q2 2025.
  • In the past 5 years, Halozyme Therapeutics' Cash & Equivalents registered a high of $499.4 million during Q1 2021, and its lowest value of $61.9 million during Q2 2025.
  • Over the past 5 years, Halozyme Therapeutics' median Cash & Equivalents value was $164.6 million (recorded in 2024), while the average stood at $217.8 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first surged by 64790.92% in 2021, then crashed by 7965.57% in 2022.
  • Halozyme Therapeutics' Cash & Equivalents (Quarter) stood at $118.7 million in 2021, then soared by 97.27% to $234.2 million in 2022, then crashed by 49.46% to $118.4 million in 2023, then decreased by 2.13% to $115.8 million in 2024, then soared by 262.25% to $419.7 million in 2025.
  • Its last three reported values are $419.7 million in Q3 2025, $61.9 million for Q2 2025, and $176.3 million during Q1 2025.